(NASDAQ: NVAX) Novavax's forecast annual revenue growth rate of -34.96% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 105.04%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.71%.
Novavax's revenue in 2025 is $1,064,651,000.On average, 11 Wall Street analysts forecast NVAX's revenue for 2025 to be $176,798,906,560, with the lowest NVAX revenue forecast at $162,498,995,000, and the highest NVAX revenue forecast at $200,361,260,835. On average, 11 Wall Street analysts forecast NVAX's revenue for 2026 to be $73,106,672,861, with the lowest NVAX revenue forecast at $46,450,337,721, and the highest NVAX revenue forecast at $157,520,025,793.
In 2027, NVAX is forecast to generate $47,607,330,565 in revenue, with the lowest revenue forecast at $21,498,617,039 and the highest revenue forecast at $78,428,514,947.